Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Consolidated Appropriations Act, 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
H.J.Res. 31, the Consolidated Appropriations Act, 2019, in relation to securing sufficient funding for the Food and Drug Administration (FDA); FY 2020 appropriations for the National Institutes of Health, the Childhood Cancer STAR Act programs at the National Cancer Institute, the Department of Defense's Congressionally Directed Medical Research Program (CDMRP) Peer Reviewed Cancer Research Program (PRCRP), and the FDA;
To provide that the rule entitled Short-Term, Limited Duration Insurance shall have no force or effect.
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) via BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
2019 · third_quarter · Q3
S 475, the RxCAP Act; Medicaid regulatory activity that include block grants, work requirements, and other erosions of Medicaid coverage and benefits; the Prescription Drug Pricing Reduction Act of 2019; out-of-pocket costs for Medicare Part D beneficiaries, including proposals to establish an out-of-pocket cap
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions; H.R. 1628, the Paid Family Leave Pilot Extension Act
Source: Senate LDA
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act, HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; Congressional hearings and oversight related to non-ACA-compliant insurance products; and LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML),
To provide that the rule entitled Short-Term, Limited Duration Insurance shall have no force or effect.
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions
To provide that the rule entitled Short-Term, Limited Duration Insurance shall have no force or effect.
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions; H.R. 1628, the Paid Family Leave Pilot Extension Act
Enewetak Atoll Cleanup Radiation Study Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions; H.R. 1628, the Paid Family Leave Pilot Extension Act
Cancer Drug Parity Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions; H.R. 1628, the Paid Family Leave Pilot Extension Act
Cancer Drug Parity Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions
Cancer Drug Parity Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act, HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; Congressional hearings and oversight related to non-ACA-compliant insurance products; and LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML),
Palliative Care and Hospice Education and Training Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act, HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; Congressional hearings and oversight related to non-ACA-compliant insurance products; and LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML),
Palliative Care and Hospice Education and Training Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions; H.R. 1628, the Paid Family Leave Pilot Extension Act
Palliative Care and Hospice Education and Training Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions
Pre-existing Conditions Protection Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions; H.R. 1628, the Paid Family Leave Pilot Extension Act
Pre-existing Conditions Protection Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions
CREATES Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions
CREATES Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions; H.R. 1628, the Paid Family Leave Pilot Extension Act
Protecting Americans with Preexisting Conditions Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions; H.R. 1628, the Paid Family Leave Pilot Extension Act
Protecting Americans with Preexisting Conditions Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions
Protecting Americans with Preexisting Conditions Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act, HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; Congressional hearings and oversight related to non-ACA-compliant insurance products; and LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML),
Protect Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions; H.R. 1628, the Paid Family Leave Pilot Extension Act
Protect Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions
PACED Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions; H.R. 1628, the Paid Family Leave Pilot Extension Act
PACED Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions
PACED Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act, HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; Congressional hearings and oversight related to non-ACA-compliant insurance products; and LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML),
Protecting Americans with Pre-existing Conditions Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions; H.R. 1628, the Paid Family Leave Pilot Extension Act
Protecting Americans with Pre-existing Conditions Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act, HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; Congressional hearings and oversight related to non-ACA-compliant insurance products; and LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML),
Protecting Americans with Pre-existing Conditions Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions
RxCAP Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
S 475, the RxCAP Act; Medicaid regulatory activity that include block grants, work requirements, and other erosions of Medicaid coverage and benefits; out-of-pocket costs for Medicare Part D beneficiaries, including proposals to establish an out-of-pocket cap
RxCAP Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HHS regulation related to eroding protections for Medicare Part D six protected classes; S 475, the RxCAP Act; S 551, the Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act; Medicaid 1115 waivers that include work requirements and other erosions of Medicaid coverage and benefits;
RxCAP Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
S 475, the RxCAP Act; Medicaid regulatory activity that include block grants, work requirements, and other erosions of Medicaid coverage and benefits; the Prescription Drug Pricing Reduction Act of 2019; out-of-pocket costs for Medicare Part D beneficiaries, including proposals to establish an out-of-pocket cap
REFUND Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HHS regulation related to eroding protections for Medicare Part D six protected classes; S 475, the RxCAP Act; S 551, the Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act; Medicaid 1115 waivers that include work requirements and other erosions of Medicaid coverage and benefits;
Preserve Access to Affordable Generics and Biosimilars Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions; H.R. 1628, the Paid Family Leave Pilot Extension Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions
Preserve Access to Affordable Generics and Biosimilars Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act, HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; Congressional hearings and oversight related to non-ACA-compliant insurance products; and LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML),
Cancer Drug Parity Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions
Cancer Drug Parity Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act, HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; Congressional hearings and oversight related to non-ACA-compliant insurance products; and LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML),
Cancer Drug Parity Act of 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions; H.R. 1628, the Paid Family Leave Pilot Extension Act
Cancer Drug Parity Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); HHS guidance on ACA section 1332 waivers; pediatric cancer research
Cancer Drug Parity Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Cancer Drug Parity Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Cancer Drug Parity Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Consolidated Appropriations Act, 2018
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Fiscal Year 2018 National Institutes of Health appropriations; Fiscal Year 2019 National Institutes of Health appropriations; Fiscal Year 2018 Department of Defense appropriations; Fiscal Year 2019 Department of Defense appropriations; Consolidated Appropriations Act, 2018 (HR 1625)
Deferment for Active Cancer Treatment Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The Deferment for Active Cancer Treatment Act (HR 2976/S 3207)
Deferment for Active Cancer Treatment Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The Deferment for Active Cancer Treatment Act (HR 2976/S 3207)
Patients' Access to Treatments Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Patients' Access to Treatments Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Patients' Access to Treatments Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
John S. McCain National Defense Authorization Act for Fiscal Year 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Fiscal Year 2019 National Institutes of Health appropriations; HR 6157, the Department of Defense Appropriations Act for FY19, specifically provisions related to the Congressionally Mandated Disease Research Programs; HR 5515, the John S. McCain National Defense Authorization Act for FY19, specifically provisions related to the Congressionally Mandated Disease Research Programs
John S. McCain National Defense Authorization Act for Fiscal Year 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Fiscal Year 2019 National Institutes of Health appropriations; HR 6157, the Department of Defense Appropriations Act for FY19, specifically provisions related to the Congressionally Mandated Disease Research Programs; HR 5515, the John S. McCain National Defense Authorization Act for FY19, specifically provisions related to the Congressionally Mandated Disease Research Programs
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Fiscal Year 2019 National Institutes of Health appropriations; HR 6157, the Department of Defense Appropriations Act for FY19, specifically provisions related to the Congressionally Mandated Disease Research Programs; HR 5515, the John S. McCain National Defense Authorization Act for FY19, specifically provisions related to the Congressionally Mandated Disease Research Programs
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Fiscal Year 2019 National Institutes of Health appropriations; HR 6157, the Department of Defense Appropriations Act for FY19, specifically provisions related to the Congressionally Mandated Disease Research Programs; HR 5515, the John S. McCain National Defense Authorization Act for FY19, specifically provisions related to the Congressionally Mandated Disease Research Programs
Childhood Cancer STAR Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Childhood Cancer STAR Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Childhood Cancer STAR Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Right to Try Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Right to Try Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Right to Try Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
RxCAP Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
RxCAP Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
RxCAP Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); HHS guidance on ACA section 1332 waivers; pediatric cancer research
RxCAP Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Fair Care Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); HHS guidance on ACA section 1332 waivers; pediatric cancer research
Fair Care Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Fair Care Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Childhood Cancer STAR Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Childhood Cancer STAR Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Childhood Cancer STAR Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Patient Advocacy Transparency Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); HHS guidance on ACA section 1332 waivers; pediatric cancer research
Patient Advocacy Transparency Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Patient Advocacy Transparency Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Deferment for Active Cancer Treatment Act of 2018
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The Deferment for Active Cancer Treatment Act (HR 2976/S 3207)
Deferment for Active Cancer Treatment Act of 2018
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The Deferment for Active Cancer Treatment Act (HR 2976/S 3207)
RACE for Children Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform
RACE for Children Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform
RACE for Children Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Graham-Cassidy Affordable Care Act Repeal legislation; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); Childhood Cancer STAR Act (HR 820/S 292); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform; Affordable Care Act market stabilization negotiations
Cancer Drug Parity Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Graham-Cassidy Affordable Care Act Repeal legislation; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); Childhood Cancer STAR Act (HR 820/S 292); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform; Affordable Care Act market stabilization negotiations
Cancer Drug Parity Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform
Cancer Drug Parity Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Graham-Cassidy Affordable Care Act Repeal legislation; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Cancer Drug Parity Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform
American Health Care Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform
American Health Care Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Graham-Cassidy Affordable Care Act Repeal legislation; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); Childhood Cancer STAR Act (HR 820/S 292); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform; Affordable Care Act market stabilization negotiations
American Health Care Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform
FDA Reauthorization Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Graham-Cassidy Affordable Care Act Repeal legislation; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); Childhood Cancer STAR Act (HR 820/S 292); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform; Affordable Care Act market stabilization negotiations
FDA Reauthorization Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform
FDA Reauthorization Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform
National Defense Authorization Act for Fiscal Year 2018
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
National Defense Authorization Act for Fy2018 (HR 2810/S 1519)
Patients' Access to Treatments Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform
Patients' Access to Treatments Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Graham-Cassidy Affordable Care Act Repeal legislation; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); Childhood Cancer STAR Act (HR 820/S 292); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform; Affordable Care Act market stabilization negotiations
Patients' Access to Treatments Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Graham-Cassidy Affordable Care Act Repeal legislation; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Patients' Access to Treatments Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform
Childhood Cancer STAR Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Graham-Cassidy Affordable Care Act Repeal legislation; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Childhood Cancer STAR Act
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Graham-Cassidy Affordable Care Act Repeal legislation; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); Childhood Cancer STAR Act (HR 820/S 292); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform; Affordable Care Act market stabilization negotiations
Right to Try Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform
Right to Try Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Graham-Cassidy Affordable Care Act Repeal legislation; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); Childhood Cancer STAR Act (HR 820/S 292); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform; Affordable Care Act market stabilization negotiations
Right to Try Act of 2017
Client: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · Firm: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Graham-Cassidy Affordable Care Act Repeal legislation; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
FY 2020 appropriations for the National Institutes of Health, the Childhood Cancer STAR Act programs at the National Cancer Institute, the Department of Defense's Congressionally Directed Medical Research Program (CDMRP) Peer Reviewed Cancer Research Program (PRCRP), and the FDA;
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) via BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
2019 · second_quarter · Q2
FY 2020 appropriations for the National Institutes of Health, the Childhood Cancer STAR Act programs at the National Cancer Institute, the Department of Defense's Congressionally Directed Medical Research Program (CDMRP) Peer Reviewed Cancer Research Program (PRCRP), and the FDA;
S 475, the RxCAP Act; Medicaid regulatory activity that include block grants, work requirements, and other erosions of Medicaid coverage and benefits; out-of-pocket costs for Medicare Part D beneficiaries, including proposals to establish an out-of-pocket cap
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act; HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; The Lower Health Care Costs Act of 2019; HR 692, the Pre-existing Conditions Protection Act of 2019; S 1125, the Protect Act; HR 965, the CREATES Act; potential regulatory activity to reform the anti-kickback statute and Stark self-referral regulations; Congressional hearings and oversight related to non-ACA-compliant insurance products; LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML); Texas v US lawsuit implications for protections for people with pre-existing conditions
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) via BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
2019 · first_quarter · Q1
H.J.Res. 31, the Consolidated Appropriations Act, 2019, in relation to securing sufficient funding for the Food and Drug Administration (FDA); FY 2020 appropriations for the National Institutes of Health, the Childhood Cancer STAR Act programs at the National Cancer Institute, the Department of Defense's Congressionally Directed Medical Research Program (CDMRP) Peer Reviewed Cancer Research Program (PRCRP), and the FDA;
HR 1730/S 741, the Cancer Drug Parity Act; HR 1010, to To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; HR 986/S 466, the Protecting Americans with Pre-existing Conditions Act, HR 647, the Palliative Care and Hospice Education and Treatment Act (PCHETA); S 64, the Preserve Access to Affordable Generics and Biosimilars Act; S 440, the Preserving Access to Cost Effective Drugs (PACED) Act; Congressional hearings and oversight related to non-ACA-compliant insurance products; and LLS plans for a clinical trial for pediatric patients diagnosed with acute myeloid leukemia (AML),
HHS regulation related to eroding protections for Medicare Part D six protected classes; S 475, the RxCAP Act; S 551, the Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act; Medicaid 1115 waivers that include work requirements and other erosions of Medicaid coverage and benefits;
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) via BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
2018 · fourth_quarter · Q4
Department of Defense appropriations FY20, specifically provisions related to the Congressionally Mandated Disease Research Programs; the National Defense Authorization Act for FY20, specifically provisions related to the Congressionally Mandated Disease Research Programs; appropriations related to the Childhood Cancer STAR Act
Cancer Drug Parity Act (HR 1409); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); HHS guidance on ACA section 1332 waivers; pediatric cancer research
Medicare Part D plan benefit design, out-of-pocket costs, and potential reforms; CMS National Coverage Decision on CAR-T therapies,
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) via BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
2018 · third_quarter · Q3
Medicare Part D plan benefit design and out-of-pocket costs
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Fiscal Year 2019 National Institutes of Health appropriations; HR 6157, the Department of Defense Appropriations Act for FY19, specifically provisions related to the Congressionally Mandated Disease Research Programs; HR 5515, the John S. McCain National Defense Authorization Act for FY19, specifically provisions related to the Congressionally Mandated Disease Research Programs
The Deferment for Active Cancer Treatment Act (HR 2976/S 3207)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) via BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
2018 · second_quarter · Q2
Fiscal Year 2019 National Institutes of Health appropriations; HR 6157, the Department of Defense Appropriations Act for FY19, specifically provisions related to the Congressionally Mandated Disease Research Programs; HR 5515, the John S. McCain National Defense Authorization Act for FY19, specifically provisions related to the Congressionally Mandated Disease Research Programs
The Deferment for Active Cancer Treatment Act (HR 2976/S 3207)
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) via BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
2018 · first_quarter · Q1
Medicare Part D plan benefit design and out-of-pocket costs; Part D protected classes protection
Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) via BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
2017 · fourth_quarter · Q4
National Institutes of Health appropriations, Department of Defense appropriations
Medicare Part D plan benefit design and out-of-pocket costs; Reducing Existing Costs Associated with Pharmaceuticals for Seniors Act of 2016 (S 2864); Part D protected classes protection
Graham-Cassidy Affordable Care Act Repeal legislation; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) via BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
2017 · third_quarter · Q3
National Defense Authorization Act for Fy2018 (HR 2810/S 1519)
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Graham-Cassidy Affordable Care Act Repeal legislation; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); Childhood Cancer STAR Act (HR 820/S 292); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform; Affordable Care Act market stabilization negotiations
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) via BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
2017 · second_quarter · 2A
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform
National Institutes of Health appropriations; Fiscal Year 2018 Labor, Health and Human Services, Education Funding Bill
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) via BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
2017 · second_quarter · Q2
National Institutes of Health appropriations; Fiscal Year 2018 Labor, Health and Human Services, Education Funding Bill
The American Health Care Act (HR 1628); The Better Care Reconciliation Act; Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the FDA Reauthorization Act (HR 2430/S. 934); the Right to Try Act (S 204, HR 878); Patients' Access to Treatments Act of 2017 (HR 2999); RACE for Children Act (HR 1231/S 456); insurance plan benefit design related to high-cost prescription drugs; clinical trial reform
Medicare Part D plan benefit design and out-of-pocket costs
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Fiscal Year 2018 National Institutes of Health appropriations; Fiscal Year 2019 National Institutes of Health appropriations; Fiscal Year 2018 Department of Defense appropriations; Fiscal Year 2019 Department of Defense appropriations; Consolidated Appropriations Act, 2018 (HR 1625)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Medicare Part D plan benefit design and out-of-pocket costs; Reducing Existing Costs Associated with Pharmaceuticals for Seniors Act of 2016 (S 2864);
National Institutes of Health appropriations
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Medicare Part D plan benefit design and out-of-pocket costs; Reducing Existing Costs Associated with Pharmaceuticals for Seniors Act of 2016 (S 2864); the C-THRU Act (S 637); The Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (S 870);
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Medicare Part D plan benefit design and out-of-pocket costs; Reducing Existing Costs Associated with Pharmaceuticals for Seniors Act of 2016 (S 2864); the C-THRU Act (S 637); The Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (S 870);
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE